Ischaemic stroke elicits a strong neuroinflammatory response, but the functional relevance
and therapeutic potential of neuroinflammation has only recently become apparent. In acute …

Sphingosine-1-phosphate (S1P) and S1P receptors (S1PR) are bioactive lipid molecules
that are ubiquitously expressed in the human body and play an important role in the immune …

Adult neurogenic niches harbor quiescent neural stem cells; however, their in vivo identity
has been elusive. Here, we prospectively isolate GFAP+ CD133+(quiescent neural stem …

Multiple sclerosis (MS) has been thought to be a complex and indecipherable disease, and
poorly understood with regards to aetiology. Here, we suggest an emphatically positive view …

Background Oral fingolimod, a sphingosine-1-phosphate–receptor modulator that prevents
the egress of lymphocytes from lymph nodes, significantly improved relapse rates and end …

Background Fingolimod (FTY720), a sphingosine-1-phosphate–receptor modulator that
prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement …

The discovery of fingolimod (FTY720/Gilenya; Novartis), an orally active immunomodulatory
drug, has opened up new approaches to the treatment of multiple sclerosis, the most …

Multiple sclerosis (MS) and neuromyelitis optica (NMO) are autoimmune demyelinating
diseases of the central nervous system (CNS), having distinct immunological and …

Fingolimod (FTY720) is a first-in-class orally bioavailable compound that has shown efficacy
in advanced clinical trials for the treatment of multiple sclerosis (MS). In vivo, fingolimod is …

Progressive phases of multiple sclerosis are associated with inhibited differentiation of the
progenitor cell population that generates the mature oligodendrocytes required for …